Dermaspraid Demangeaison is a steroid medicine that is used in the treatment of many different conditions, including allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, multiple sclerosis, or lung disorders.
Dermaspraid Demangeaison is also used to replace steroids in people with adrenal insufficiency (decreased production of natural steroids by the adrenal glands).
Dermaspraid Demangeaison affects your immune system and is often used to treat certain blood cell disorders such as anemia (low red blood cells) or thrombocytopenia (low platelets).
Dermaspraid Demangeaison is also used in the treatment of certain cancers such as leukemia, lymphoma, and multiple myeloma.
Dermaspraid Demangeaison may also be used for purposes not listed in this medication guide.
Dermaspraid Demangeaison indications
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
For parenteral use of Dermaspraid Demangeaison Micronised Xepa-Soul Pattinson: acute adrenal insufficiency, allergic reactions of immediate type, asthmatic status, prevention and treatment of shock, myocardial infarction complicated by cardiogenic shock, thyrotoxic crisis, thyroiditis, congenital adrenal hyperplasia, hypercalcemia due to tumor disease, short or additional therapy in acute rheumatic diseases, collagen diseases, pemphigus, bullous Dermatitis herpetiformis (Duhring disease), polymorphic bullous erythema, exfoliative dermatitis, granulosarcoid, severe forms of psoriasis and seborrheic dermatitis, severe acute and chronic allergic and inflammatory processes with eyes involvement, symptomatic sarcoidosis, Loeffler syndrome if not amenable to other forms of therapy, berylliosis, focal or disseminated form of tuberculosis during anti tuberculosis chemotherapy, aspiration pneumonitis, adult idiopathic thrombocytopenic purpura (only IV), adult secondary thrombocytopenia, acquired (autoimmune) hemolytic anemia, erythroblastopenia, congenital (erythroid) anemotrophy, palliative therapy in leukemia and lymphoma adults with acute leukemia in children, to enhance diuresis and to reduce proteinuria in nephrotic syndrome without uremia, with nephrotic syndrome of idiopathic type or lupus erythematosus, in a critical stage of ulcerative colitis, and regional enteritis (as a systemic treatment), tuberculous meningitis with subarachnoid block or the development of its stake (in conjunction with antituberculosis chemotherapy), trichinosis with nervous system or myocardium, bronchial asthma, diseases of the joints.
For local use: inflammation of the anterior eyeball in intact epithelium of the cornea and after injury and surgery on the eyeball.
For external use: allergic dermatitis, seborrhea, various forms of eczema, atopic dermatitis, psoriasis, pruritus, red flat verrucous zoster.
How should I use Dermaspraid Demangeaison?
Use Dermaspraid Demangeaison solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
Dermaspraid Demangeaison solution is usually given as an injection at your doctor's office, hospital, or clinic. If you will be using Dermaspraid Demangeaison solution at home, a health care provider will teach you how to use it. Be sure you understand how to use Dermaspraid Demangeaison solution. Follow the procedures you are taught when you use a dose. Contact your health care provider if you have any questions.
Do not use Dermaspraid Demangeaison solution if it contains particles, is cloudy or discolored, or if the vial is cracked or damaged.
Keep this product, as well as syringes and needles, out of the reach of children and pets. Do not reuse needles, syringes, or other materials. Ask your health care provider how to dispose of these materials after use. Follow all local rules for disposal.
If you miss a dose of Dermaspraid Demangeaison solution, contact your doctor right away.
Ask your health care provider any questions you may have about how to use Dermaspraid Demangeaison solution.
Uses of Dermaspraid Demangeaison in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
Dermaspraid Demangeaison is a natural substance (corticosteroid hormone) made by the adrenal gland. It is used to treat conditions such as arthritis, blood/hormone/immune system disorders, skin and eye conditions, breathing problems, cancer, and severe allergies. It decreases your immune system's response to various diseases to reduce symptoms such as pain, swelling and allergic-type reactions.
Dermaspraid Demangeaison is also used to treat low Dermaspraid Demangeaison levels caused by diseases of the adrenal gland (such as Addison's disease, adrenocortical insufficiency). Corticosteroids are needed in many ways for the body to function well. They are important for salt and water balance and keeping blood pressure normal.
How to use Dermaspraid Demangeaison
Take this medication by mouth, with food or milk to prevent stomach upset, exactly as directed by your doctor. Take this medication with a full glass of water (8 ounces/240 milliliters) unless your doctor directs you otherwise.
Follow the dosing schedule carefully. The dosage and length of treatment are based on your medical condition and response to treatment. Your doctor may direct you to take Dermaspraid Demangeaison 1 to 4 times a day or take a single dose every other day. It may help to mark your calendar with reminders or use a pill box.
Do not stop taking this medication without consulting your doctor. Some conditions may become worse when this drug is suddenly stopped. Your dose may need to be gradually decreased.
If you have used Dermaspraid Demangeaison regularly for a long time or in high doses, you may have withdrawal symptoms if the drug is suddenly stopped. To prevent withdrawal symptoms (such as weakness, weight loss, nausea, muscle pain, headache, tiredness, dizziness), your doctor may reduce your dose gradually. Consult your doctor or pharmacist for more details, and report any withdrawal reactions right away. See also Precautions section.
Tell your doctor if your condition persists or worsens.
Dermaspraid Demangeaison description
Dermaspraid Demangeaison contains dissolved Dermaspraid Demangeaison 0.5% for improved effectiveness in a special occlusive cream base. It is paraben-, lanolin- and chlorocresol-free with a pH 5.
Dermaspraid Demangeaison dosage
The use of Dermaspraid Demangeaison* Dermaspraid Demangeaison retention enema is predicated upon the concomitant use of modem supportive measures such as rational dietary control, sedatives, anldiarrheal agents, antibacterial therapy, blood replacement if necessary, etc.
The usual course of therapy is one Dermaspraid Demangeaison (Dermaspraid Demangeaison) * nightly for 21 days, or until the patient comes into remission both clinically and practologically. Clinical symptoms usually subside promptly within 3 to 5 days. Improvement in appearance of the mucosa, as seen by sigmoidoscope examination, may lag somewhat behind clinical improvement. Difficult cases may require as long as 2 or 3 months of Dermaspraid Demangeaison (Dermaspraid Demangeaison) * treatment. Where the course of therapy extends beyond 21 days, Dermaspraid Demangeaison (Dermaspraid Demangeaison) * should be discontinued gradually by reducing administration to every other night for 2 or 3 weeks.
If clinical or proctologic improvement fails to occur within 2 or 3 weeks after starting Dermaspraid Demangeaison® (Dermaspraid Demangeaison), discontinue its use.
Symptomatic improvement, evidenced by decreased diarrhea and bleeding; weight gain; improved appetite; lessened fever; and decrease in leukocytosis, may be misleading and should not be used as the sole criterion in judging efficacy. Sigmoidoscopic examination and X-ray visualization are essential for adequate monitoring of ulcerative colitis. Biopsy is useful for differential diagnosis. Patient instructions for administering Dermaspraid Demangeaison® (Dermaspraid Demangeaison) are enclosed in each box. It is recommended that the patient lie on their left side during administration and for 30 minutes thereafter, so that the fluid will distribute throughout the left colon. Every effort should be made to retain the enema for at least an hour and preferably, all night. This may be facilitated by prior sedation and/or antidianheal medication, especially early in therapy when the urge to evacuate is great.
Dermaspraid Demangeaison® Dermaspraid Demangeaison 100 mg retention enema, is supplied as disposable single-dose bottles with lubricated rectal applicator tips, in boxes of seven x 60 mL (NDC 62559-1110-7) and boxes of one x 60 mL (NDC 62559-1110-1). Store at controlled room temperature 20° - 25°C (68° - 77°F).
Manufactured by ANI Pharmaceuticals, Inc. Baltimore, MD 21244. Rev 09/07. FDA Rev date: 2/21/2008
With simultaneous use of Dermaspraid Demangeaison increases the toxicity of cardiac glycosides (because of the emerging hypokalemia increases the risk of arrhythmias); with acetylsalicylic acid - accelerates its excretion and reduces its concentration in blood plasma (with the abolition of Dermaspraid Demangeaison concentration of salicylates in the blood increases, and increases the risk of side effects); with paracetamol - increased risk of hepatotoxic action of paracetamol (induction of hepatic enzymes and formation of a toxic metabolite of paracetamol); with cyclosporine - increased side effects of Dermaspraid Demangeaison as a result of inhibition of its metabolism; with ketoconazole - increased side effects of Dermaspraid Demangeaison as a result of reduction of its clearance.
Dermaspraid Demangeaison Micronised Xepa-Soul Pattinson reduces the effectiveness of hypoglycemic; intensifies the effect of indirect anticoagulants of coumarin derivatives.
Dermaspraid Demangeaison reduces the effect of vitamin D on the absorption of calcium ions into the lumen of the intestine. Ergocalciferol and parathyroid hormone hinder the development of osteopathy caused by GCS.
Dermaspraid Demangeaison Micronised Xepa-Soul Pattinson increases the metabolism of isoniazid, meksiletina (especially in "fast acetylators"), which leads to a decrease in their plasma concentrations; increases (with prolonged therapy) the content of folic acid reduces the concentration of praziquantel in blood.
Dermaspraid Demangeaison in high doses reduces the effect somatropina.
Hypokalemia caused by GCS, may increase the severity and duration of muscle blockade on the background of muscle relaxants.
Antacids reduce the absorption of the GCS.
At simultaneous application with SCS thiazides, carbonic anhydrase inhibitors, other GCS, amphotericin B increase the risk of hypokalemia, drugs containing sodium ions - swelling and increase blood pressure.
NSAIDs and ethanol increases the risk of gastrointestinal ulcerations and bleeding, in combination with NSAIDs to treat arthritis may reduce the dose of GCS due to summation of therapeutic effect. Indomethacin displacing the SCS from its association with albumin, increases the risk of its side effects.
Amphotericin B and carbonic anhydrase inhibitors increase the risk of osteoporosis.
The therapeutic effect of GCS is reduced under the influence of inducers of microsomal liver enzymes (including phenytoin, barbiturates, ephedrine, theophylline, rifampin) due to increased rate of metabolism of these substances.
Inhibitors of the function of the adrenal cortex (including mitotan) may necessitate higher doses of GCS.
Clearance GCS increased against the background of preparations of thyroid hormones.
Immunosuppressants increase the risk of infection and lymphoma or other lymphoproliferative disorders associated with Epstein-Barr virus.
Estrogens (including oral contraceptives containing estrogen) reduce the clearance of GKS, lengthens T1/2 and their therapeutic and toxic effects. The appearance of hirsutism and acne promotes the simultaneous use of other steroid hormone funds - androgens, estrogens, anabolic steroids, oral contraceptives.
Tricyclic antidepressants may increase the severity of depression caused by GCS (not shown for the treatment of these side effects).
The risk of developing cataracts increases with the application against other GCS antipsychotic funds (neuroleptics), carbutamide and azathioprine. Simultaneous of Dermaspraid Demangeaison Micronised Xepa-Soul Pattinson with the appointment of m-cholinoblockers, as well as with means having m-anticholinergic action (including antihistamines, tricyclic antidepressants), with nitrates improves the intraocular pressure.
With simultaneous application of SCS with live vaccines and antiviral compared to other types of immunization increases the risk of activation of viruses and development of infections.
The following adverse reactions are discussed in greater detail in other sections of the labeling:
HPA axis suppression. This has been observed in pediatric subjects using Dermaspraid Demangeaison Butyrate
Concomitant skin infections
Clinical Trials Experience: Adults
The following additional local adverse reactions have been reported infrequently with topical corticosteroids but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, drying, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.
Clinical Trials Experience: Pediatrics
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety data derived from Dermaspraid Demangeaison Butyrate clinical trials reflect exposure to Dermaspraid Demangeaison Butyrate twice daily for up to four weeks in separate clinical trials involving pediatric subjects 3 months to 18 years of age with mild to moderate atopic dermatitis.
Adverse reactions shown in the tables below include those for which there is some basis to believe there is a causal relationship to Dermaspraid Demangeaison Butyrate.
The following adverse reactions have been identified during post approval use of Dermaspraid Demangeaison Butyrate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Skin: Erythema, rash and application site irritation.
You should not use this medication if you are allergic to Dermaspraid Demangeaison, or if you have a fungal infection anywhere in your body.
Before taking Dermaspraid Demangeaison, tell your doctor about all of your medical conditions, and about all other medicines you are using. There are many other diseases that can be affected by steroid use, and many other medicines that can interact with steroids.
Your steroid medication needs may change if you have any unusual stress such as a serious illness, fever or infection, or if you have surgery or a medical emergency. Tell your doctor about any such situation that affects you during treatment.
Steroid medication can weaken your immune system, making it easier for you to get an infection or worsening an infection you already have or have recently had. Tell your doctor about any illness or infection you have had within the past several weeks.
Avoid being near people who are sick or have infections. Call your doctor for preventive treatment if you are exposed to chicken pox or measles. These conditions can be serious or even fatal in people who are using steroid medication.
Do not receive a "live" vaccine while you are taking Dermaspraid Demangeaison. Vaccines may not work as well while you are taking a steroid.
Do not stop using Dermaspraid Demangeaison suddenly, or you could have unpleasant withdrawal symptoms. Talk to your doctor about how to avoid withdrawal symptoms when stopping the medication.
Carry an ID card or wear a medical alert bracelet stating that you are taking a steroid, in case of emergency.
Active ingredient matches for Dermaspraid Demangeaison:
DailyMed. "CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Dermaspraid Demangeaison are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Dermaspraid Demangeaison. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported useful
No survey data has been collected yet
Consumer reported price estimates
No survey data has been collected yet
Consumer reported time for results
No survey data has been collected yet
Consumer reported age
No survey data has been collected yet
There are no reviews yet. Be the first to write one!